Brief: Genetic Signatures Says Influenza B Detection Expected To Impact On Quarter Sales

Genetic Signatures

25/08/2023 02:17

Aug 25 (Reuters) - Genetic Signatures Ltd  GSS.AX :
    * INFLUENZA B DETECTION EXPECTED TO IMPACT ON QUARTER SALES
    * A UNDERTAKEN AN INVESTIGATION
    * WELL-ADVANCED IN RESOLVING THE ISSUE, WHICH IS SPECIFIC TO
INFLUENZA B VIRUS
    * FOUND SEASON'S INFLUENZA B VIRUS IS NOT BEING CONSISTENTLY
DETECTED IN A SMALL PROPORTION OF LOW VIRAL CONCENTRATION
SAMPLES
    * AT THIS TIME, WE EXPECT FORECAST REVENUE TO BE ABOUT A$2
MILLION
FOR Q1 FY2023
    * DETECTION OF INFLUENZA A VIRUS IS UNAFFECTED.
    * IN INTERIM, SALE OF GENETIC SIGNATURES EASYSCREEN™
RESPIRATORY
PATHOGEN DETECTION KIT HAS BEEN IMPACTED DURING THIS CURRENT
QUARTER

Source text for Eikon:  ID:nASX43JQLy 
Further company coverage:  GSS.AX